Alzheimer's Disease Clinical Trials

40 studies are recruiting for alzheimer's disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

   The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Chandler Clinical Trials, LLC, Chandler, Arizona

   Locations

   143 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07011745 on ClinicalTrials.gov

2. PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

   Background: About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflam…

   Stage

   Phase 1

   Ages

   50 to 100

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Mental Health (NIMH)

   See if you can join NCT07169630 on ClinicalTrials.gov

3. Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin

   Background: Normal aging, as well as dementias such as Alzheimer s disease, can cause changes in the brain that affect memory, attention, and thinking. Researchers want to know if regular mental tasks (cognitive training) can improve brain function in older adults. They also want to know if psilocy…

   Stage

   Phase 2

   Ages

   65 to 120

   Site

   National Institute of Aging, Clinical Research Unit, Baltimore, Maryland

   Run by

   National Institute on Aging (NIA)

   See if you can join NCT07721467 on ClinicalTrials.gov

4. PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

   Background: About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation. Objective: To learn wh…

   Stage

   Phase 1

   Ages

   18 to 99

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Mental Health (NIMH)

   See if you can join NCT04396873 on ClinicalTrials.gov

5. An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

   VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

   Stage

   Phase 1

   Ages

   30 to 80

   Site

   K2 Medical Research, LLC, Maitland, Florida

   Locations

   2 in total

   Run by

   Voyager Therapeutics

   See if you can join NCT07764146 on ClinicalTrials.gov

6. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

   The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

   Stage

   Phase 3

   Ages

   60 to 85

   Site

   Healthy Brain Clinic, Long Beach, California

   Locations

   119 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT06976216 on ClinicalTrials.gov

7. A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

   This is a randomized, placebo-controlled Phase 2 study to evaluate the efficacy and safety of SAR448851 in early Alzheimer's disease (AD) participants. The purpose of this study is to measure efficacy and safety with once daily oral SAR448851 compared to placebo in participants with mild cognitive …

   Stage

   Phase 2

   Ages

   55 to 85

   Site

   Healthy Brain Clinic- Site Number : 8400011, Long Beach, California

   Locations

   20 in total

   Run by

   Sanofi

   See if you can join NCT07688213 on ClinicalTrials.gov

8. Choose Myself (Before) Losing Myself

   The purpose of this study is to see if an educational interactive booklet about how dementia progresses throughout a person's life can be a helpful tool for patients to think about future decisions that might need to be made regarding their medical care and helping patients discuss their diagnosis …

   Stage

   Not phased

   Ages

   18 and older

   Site

   The Cleveland Clinic, Cleveland, Ohio

   Run by

   The Cleveland Clinic

   See if you can join NCT07846566 on ClinicalTrials.gov

9. Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

   The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.

   Stage

   Not phased

   Ages

   18 and older

   Site

   The Ohio State University, Columbus, Ohio

   Run by

   Douglas Scharre

   See if you can join NCT03019757 on ClinicalTrials.gov

10. Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study

    The purpose of this study is to see if a special light treatment, called photobiomodulation, can help people with memory problems such as Mild Cognitive Impairment or Mild Dementia due to Alzheimer's disease. The light is given to the forehead using an FDA-cleared medical device. This device is cle…

    Stage

    Not phased

    Ages

    55 to 89

    Site

    CSMC, Los Angeles, California

    Run by

    Cedars-Sinai Medical Center

    See if you can join NCT07224607 on ClinicalTrials.gov

11. CommunityRx-Dementia + Peer Navigation (CRxDpeer)

    The CRxDpeer intervention, delivered by a trained peer navigator, in practice called a "peer mentor", includes three evidence-based components: (a) focused education about common social (e.g., food and housing insecurity) and caregiving (e.g., respite and end of life care) needs, (b) activation of …

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Chicago, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT07346183 on ClinicalTrials.gov

12. A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

    This study will evaluate the efficacy and safety of trontinemab in participants with biomarker evidence of Alzheimer's Disease (AD) pathology but with no cognitive or functional impairment, who are at risk for progression to mild cognitive impairment (MCI) due to AD or dementia due to AD.

    Stage

    Phase 3

    Ages

    55 to 80

    Site

    Irvine Center for Clinical Research, Irvine, California

    Locations

    34 in total

    Run by

    Hoffmann-La Roche

    See if you can join NCT07717411 on ClinicalTrials.gov

13. A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

    Stage

    Phase 3

    Ages

    60 to 85

    Site

    Fullerton Neurology and Headache Center, Fullerton, California

    Locations

    128 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT06976203 on ClinicalTrials.gov

14. Wake Forest Alzheimer's Disease Clinical Core

    Efforts to find treatments for AD have yielded only modest benefits, likely because longstanding AD pathological processes induce irreversible neurological compromise. These processes begin years before the onset of clinical symptoms. This possibility has been incorporated into a model describing s…

    Stage

    Not phased

    Ages

    55 and older

    Site

    Wake Forest Baptist Health, Winston-Salem, North Carolina

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT03140865 on ClinicalTrials.gov

15. Ultrasonic Debris Clearance to Promote Brain Resilience

    This pilot study will evaluate the safety, tolerability, and feasibility of Ultrasonic Debris Clearance (UDC), a noninvasive low-intensity focused ultrasound intervention, in amyloid-positive adults who are asymptomatic but at risk for Alzheimer's disease, or who have mild cognitive impairment or m…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Stanford University, Stanford, California

    Run by

    Stanford University

    See if you can join NCT07573982 on ClinicalTrials.gov

16. Dominantly Inherited Alzheimer Network (DIAN)

    The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mayo Clinic Jacksonville, Jacksonville, Florida

    Locations

    26 in total

    Run by

    Washington University School of Medicine

    See if you can join NCT00869817 on ClinicalTrials.gov

17. NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE

    The goal of this clinical trial is to learn if repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, can improve short-term memory in people with early Alzheimer's disease (AD). The study will also evaluate the safety of this approach. The main questions it …

    Stage

    Not phased

    Ages

    55 to 90

    Site

    Baylor College of Medicine, Houston, Texas

    Run by

    Chi-Ying (Roy) Lin

    See if you can join NCT07667478 on ClinicalTrials.gov

18. A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

    The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration

    Stage

    Phase 1

    Ages

    18 to 80

    Site

    CenExel ACT (Formerly Anaheim Clinical Trials; LLC), Anaheim, California

    Locations

    6 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07780383 on ClinicalTrials.gov

19. Comparison of Two Group Wellness Interventions for Individuals With Neurologic Conditions and Their Support Persons

    Approximately 5.3 million people live with a long-term disability resulting from a traumatic brain injury (TBI) and between 5-8% of those older than 60 suffer from Alzheimer's disease or other forms of dementia (ADRD). Consequences of these conditions can result in dramatic and persistent changes i…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Kessler Foundation, East Hanover, New Jersey

    Run by

    Kessler Foundation

    See if you can join NCT05048966 on ClinicalTrials.gov

20. A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

    Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Clinical symptoms of the disease may begin with occasional forgetfulness such as misplacement of items, forgetting important dates or events, and may pro…

    Stage

    Phase 1

    Ages

    50 to 90

    Site

    Irvine Center for Clinical Research /ID# 277752, Irvine, California

    Locations

    13 in total

    Run by

    AbbVie

    See if you can join NCT07599670 on ClinicalTrials.gov

21. Pulsed Electromagnetic Field Treatment With Dementia Patients

    An open label pilot study in mild to moderate AD/ADRD patients to assess the effects of treatment with ECHS AD/ADRD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices. They will treat themselves at home three times a day for 15 minutes over…

    Stage

    Not phased

    Ages

    50 to 100

    Site

    University of Miami, Boca Raton, Florida

    Run by

    Herrick Medical LLC

    See if you can join NCT06862557 on ClinicalTrials.gov

22. A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease

    The primary purpose of this study is to evaluate the safety of lecanemab-irmb in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemo…

    Stage

    Not phased

    Ages

    Any age

    Site

    Eisai Trial Site #1, Nutley, New Jersey

    Run by

    Eisai Inc.

    See if you can join NCT07821658 on ClinicalTrials.gov

23. Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)

    To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide …

    Stage

    Not phased

    Ages

    18 to 120

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    2 in total

    Run by

    University of Pennsylvania

    See if you can join NCT05658913 on ClinicalTrials.gov

24. Central Auditory Processing Modulation Underlying Anxiety Reduction Using Clinically Designed Improvisatory Music

    This study examines whether Clinically Designed Improvisatory Music (CDIM) can reduce anxiety in people living with Alzheimer's disease and anxiety (AD-A), and whether it can also lessen caregiver burden. CDIM is a live, receptive music-based intervention that uses slow tempi, simple diatonic melod…

    Stage

    Not phased

    Ages

    55 and older

    Site

    Northwestern University Feinberg School of Medicine, Chicago, Illinois

    Run by

    Northwestern University

    See if you can join NCT07775625 on ClinicalTrials.gov

25. Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

    This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.

    Stage

    Not phased

    Ages

    40 to 90

    Site

    Insigth Hospital and Medical Center Chicago, Chicago, Illinois

    Locations

    5 in total

    Run by

    Neurogen Biomarking LLC

    See if you can join NCT07701161 on ClinicalTrials.gov